Goldman Sachs Group Inc Kala Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$0.25 - $11.7 $58,294 - $2.73 Million	-233,177 Reduced 95.6%	10,741 $2,000
Q3 2022 Nov 10, 2022	SELL	$0.25 - $11.7 $58,294 - $2.73 Million	-233,177 Reduced 95.6%	10,741 $0
Q2 2022 May 14, 2024	BUY	$0.3 - $1.31 $73,175 - $319,532	243,918 New	243,918 $74,000
Q2 2022 Aug 15, 2022	BUY	$0.3 - $1.31 $46,426 - $202,730	154,756 Added 173.57%	243,918 $74,000
Q1 2022 May 16, 2022	SELL	$0.61 - $1.84 $69,754 - $210,407	-114,352 Reduced 56.19%	89,162 $123,000
Q4 2021 Feb 14, 2022	BUY	$1.16 - $2.74 $56,326 - $133,046	48,557 Added 31.34%	203,514 $246,000
Q3 2021 Nov 10, 2021	BUY	$2.62 - $5.43 $405,987 - $841,416	154,957 New	154,957 $406,000

Ticker KALA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 1,464,160
Market Cap $9.05M
Description
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.